Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by independent educational grants from Astellas Pharma Global Development, Inc., Celgene Corporation, and Jazz Pharmaceuticals.
Managing the Continuum of Myeloid Malignancies (CML, MPN, MDS, and AML)
Andrew Artz, MS, MD
University of Chicago Medicine
Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
University of Chicago Medicine
Take a deep dive into the updated WHO criteria for diagnosing myeloid malignancies, the mechanisms of action of new novel therapies, and the growing role of molecular mutations, while also learning how to take a collaborative, multidisciplinary approach to classifying these diseases. Advanced practitioners are key to managing the evolving continuum of myeloid malignancies and creating a multidisciplinary team approach to managing patients with complex myeloid malignancies.
These CME/CE/CPE accredited activities are jointly provided by
